natgillin/translations-raw huggingface dataset:
NAME OF THE MEDICINAL PRODUCT ZYPREXA 20 mg coated tablets olanzapine
ZYPREXA 20 mg obložene tablete olanzapin
Do not take ZYPREXA
ZYPREXA.
Only take other medicines while you are on ZYPREXA if your doctor tells you that you can. You might feel drowsy if ZYPREXA is taken in combination with antidepressants or medicines taken for anxiety or to help you sleep (tranquillisers).
Ako uzimate lijek ZYPREXA u kombinaciji s antidepresivima, lijekovima za tjeskobu ili lijekovima koji
See also information under the heading “Do not take Ifirmasta”.
Vidjeti također informacije pod naslovom “Nemojte uzimati Ifirmastu”.
You can take Ifirmasta with or without food.
Ifirmastu možete uzeti s hranom ili bez nje.
Ifirmasta should not be given to children under 18 years of age.
Ifirmasta se ne smije davati djeci mlađoj od 18 godina.
However the terminal halflife was not significantly altered.
Međutim, terminalni poluvijek nije bio značajno promijenjen.
It is important that you continue to take Ifirmasta until your doctor tells you otherwise.
Važno je da nastavite uzimati Ifirmastu sve dok Vam liječnik ne kaže drugačije.
What Ifirmasta is and what it is used for
Što je Ifirmasta i za što se koristi
This medicine should not be used in children and adolescents (< 18 years) because the safety and efficacy have not yet been fully established.
Ovaj lijek ne smiju uzimati djeca ni adolescenti (< 18 godina) jer sigurnost i djelotvornost lijeka nisu još u potpunosti utvrđene.
The expiry date refers to the last day of that month.
Rok valjanosti odnosi se na zadnji dan tog mjeseca.
The safety and efficacy of Ifirmasta in children aged 0 to 18 has not been established.
Sigurnost i djelotvornost lijeka Ifirmasta u djece u dobi od 0 do 18 godina nisu ustanovljene.
- Patients with high blood pressure
- Bolesnici s visokim krvnim tlakom
If you forget to take Ifirmasta
Ako ste zaboravili uzeti Ifirmastu
White, oval tablets.
Bijele, ovalne tablete.
Date of first authorisation: 1 December 2008 Date of latest renewal: 26 August 2013
Datum posljednje obnove: 26. kolovoza 2013.
If you accidentally miss a daily dose, just take the next dose as normal.
Ako slučajno zaboravite uzeti dnevnu dozu, uzmite sljedeću dozu kao i obično.
What Ifirmasta contains - The active substance is irbesartan.
Što Ifirmasta sadrži - Djelatna tvar je irbesartan.
Swallow the tablets with a sufficient amount of fluid (e.g. one glass of water).
Progutajte tablete s dovoljnom količinom tekućine (npr. jedna čaša vode).
What you need to know before you take Ifirmasta
Što morate znati prije nego počnete uzimati Ifirmastu
Other medicines and Ifirmasta
Drugi lijekovi i Ifirmasta
hepatitis, abnormal liver function
hepatitis, abnormalna funkcija jetre
Your doctor will normally advise you to stop taking Ifirmasta before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Ifirmasta.
Liječnik će Vam obično preporučiti da prestanete uzimati Ifirmastu prije nego što zatrudnite ili čim saznate da ste trudni te će Vam savjetovati uzimanje drugog lijeka umjesto Ifirmaste.
No specific information is available on the treatment of overdosage with Ifirmasta.
Nema dostupnih specifičnih podataka o liječenju predoziranja Ifirmastom.
Less than 2% of the dose is excreted in the urine as unchanged irbesartan.
Manje od 2% doze izlučuje se urinom u obliku nepromijenjenog irbesartana.
What Ifirmasta is and what it is used for What you need to know before you take Ifirmasta How to take Ifirmasta
Što se nalazi u ovoj uputi Što je Ifirmasta i za što se koristi Što morate znati prije nego počnete uzimati Ifirmastu Kako uzimati Ifirmastu
Therefore, the use of Ifirmasta is not recommended.
Stoga se ne preporučuje primjena Ifirmaste.
After oral administration, irbesartan is well absorbed: studies of absolute bioavailability gave values of approximately 60-80%.
Nakon peroralne primjene irbesartan se dobro apsorbira: ispitivanja apsolutne bioraspoloživosti pokazala su vrijednosti oko 60-80%.
IDNT was a double blind, controlled, morbidity and mortality trial comparing irbesartan, amlodipine and placebo.
IDNT je bila dvostruko slijepa, kontrolirana studija morbiditeta i mortaliteta u kojoj su uspoređivani irbesartan, amlodipin i placebo.
Irbesartan has been studied in paediatric populations aged 6 to 16 years old but the current data are insufficient to support an extension of the use in children until further data become available (see sections 4.8, 5.1 and 5.2).
Irbesartan je ispitivan na pedijatrijskoj populaciji u dobi od 6 do 16 godina, ali trenutni podaci nisu dostatni da bi podržali proširenje primjene na djecu, sve dok ne budu dostupni i daljnji podaci (vidjeti dijelove 4.8, 5.1 i 5.2).
When the individual components of the primary endpoint were analysed, no effect in all cause mortality was observed, while a positive trend in the reduction in ESRD and a significant reduction in doubling of serum creatinine were observed.
Kada su se analizirale individualne komponente primarnog ishoda, nisu zabilježeni učinci na sve uzroke smrtnosti, dok je zabilježen pozitivan trend u smanjenju terminalne faze bubrežne bolesti i značajno smanjenje u udvostručavanju serumskog kreatinina.
When driving vehicles or operating machines, it should be taken into account that dizziness or weariness may occur during treatment.
Prilikom upravljanja vozilima ili rukovanja strojevima, potrebno je uzeti u obzir mogućnost pojave omaglice ili umora tijekom liječenja.
If you experience these, talk to your doctor before attempting to drive or use machines.
Ako to osjetite, savjetujte se sa svojim liječnikom prije nego što pokušate voziti ili upravljati strojevima.
Ifirmasta is unlikely to affect your ability to drive or use machines.
Nije vjerojatno da bi Ifirmasta utjecala na Vašu sposobnost upravljanja vozilima ili rukovanja strojevima.
Such conditions should be corrected before the administration of Ifirmasta.
Takva stanja treba korigirati prije primjene Ifirmaste.
Pharmacotherapeutic group: angiotensin II antagonist, plain, ATC code: C09CA04.
Farmakoterapijska skupina: antagonisti angiotenzina II, čisti, ATK oznaka: C09CA04.
Although consideration should be given to initiating therapy with 75 mg in patients over 75 years of age, dose adjustment is not usually necessary for older people.
Iako za bolesnike starije od 75 godina treba razmotriti započinjanje terapije dozom od 75 mg, dozu obično nije potrebno prilagoditi u starijih osoba.
Do not use this medicine after the expiry date which is stated on the carton and on the blister after EXP.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na pakiranju i blisteru iza oznake „EXP“.
Activated charcoal may be useful in the treatment of overdosage.
Za liječenje predoziranja može biti koristan aktivni ugljen.
Ifirmasta is indicated in adults for the treatment of essential hypertension.
Ifirmasta je indicirana za liječenje esencijalne hipertenzije u odraslih.
In the 26-week open-label period of this trial the most frequent laboratory abnormalities observed were creatinine increases (6.5%) and elevated CK values in 2% of child recipients.
U otvorenom razdoblju ovog ispitivanja, u trajanju od 26 tjedana, najčešće opažene laboratorijske abnormalnosti bile su povećana koncentracija kreatinina (6,5%) i povišene vrijednosti CK u 2% djece koja su primila lijek.
In particular, they appeared less favourable in women and non-white subjects (see section 5.1).
Posebice je bio slabije izražen u žena i bolesnika koji nisu pripadali bijeloj rasi (vidjeti dio 5.1).
In particular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive effect with Ifirmasta (see section 4.5).
Osobito se pokazalo da dodavanje diuretika kao što je hidroklorotiazid ima aditivni učinak uz Ifirmastu (vidjeti dio 4.5).
The frequency of the side effects listed below is defined using the following convention: Very common: may affect more than 1 in 10 people Common: may affect up to 1 in 10 people
Učestalost dolje navedenih nuspojava definirana je na sljedeći način: Vrlo često: mogu se javiti u više od 1 na 10 osoba
Ifirmasta is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.
Ifirmasta se ne preporučuje majkama koje doje, a Vaš liječnik može izabrati drugu terapiju ako želite dojiti, osobito ako se radi o dojenju novorođenčeta ili nedonoščeta.
Irbesartan significantly reduced the relative risk in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or allcause mortality.
Irbesartan je značajno snizio relativni rizik u primarnoj kombiniranoj mjeri ishoda udvostručenog serumskog kreatinina, terminalne faze bubrežne bolesti ili svih uzroka mortaliteta.
Ifirmasta at a dose of 150 mg once daily generally provides a better 24 hour blood pressure control than 75 mg.
Doza od 150 mg Ifirmaste jedanput na dan općenito osigurava bolju kontrolu krvnog tlaka u razdoblju od 24 sata nego doza od 75 mg.
No dosage adjustment is necessary in older people.
Stoga, nije potrebna prilagodba doze u starijih osoba.
The maximal blood pressure lowering effect should be reached 4-6 weeks after beginning treatment.
Maksimalni učinak na sniženje krvnog tlaka trebao bi se postići za 4-6 tjedana od početka liječenja.
In this case your doctor may perform regular blood tests, especially for measuring blood potassium levels in case of poor kidney function, - if you are going to have an operation (surgery) or be given anaesthetics,
U tom će Vam slučaju Vaš liječnik možda raditi redovite pretrage krvi, posebno određivanje koncentracije kalija u krvi u slučaju oslabljene funkcije bubrega, - ako trebate ići na bilo kakav kirurški zahvat ili trebate primiti anestetike,
Blister (PVC/PE/PVDC/Alu): 56 x 1 film-coated tablets in perforated unit dose blisters in box.
Blister (PVC/PE/PVDC/Al): 56 x 1 filmom obloženih tableta u perforiranim blisterima djeljivim na jedinične doze, u kutiji.
hypersensitivity reactions such as angioedema, rash, urticaria, anaphylactic reaction, anaphylactic shock
reakcije preosjetljivosti kao što su angioedem, osip, urtikarija, anafilaktička reakcija, anafilaktički šok
How to take Ifirmasta
Kako uzimati Ifirmastu
The usual dose is 150 mg once a day (two tablets a day).
Uobičajena doza iznosi 150 mg jednom na dan (dvije tablete na dan).
Polyvinyl alcohol Titanium dioxide (E171) Macrogol 3000
Film ovojnica: poli (vinilni alkohol) titanijev dioksid (E171) makrogol 3000 talk
The usual dose is 150 mg once a day.
Uobičajena doza iznosi 150 mg jednom na dan.
While this is not documented with Ifirmasta, a similar effect should be anticipated with angiotensin-II receptor antagonists.
Iako to još nije potvrđeno za Ifirmastu, sličan učinak može se očekivati s antagonistima receptora angiotenzina II.
vertigo, headache
vrtoglavica, glavobolja
The blood pressure lowering effect of irbesartan is evident within 1-2 weeks, with the maximal effect occurring by 4-6 weeks after start of therapy.
Učinak irbesartana na snižavanje krvnog tlaka vidljiv je unutar 1-2 tjedna, s maksimalnim učinkom za 4-6 tjedana od početka terapije.
Blister (PVC/PE/PVDC/Alu): 14, 28, 30, 56, 84, 90 or 98 film-coated tablets in box are available.
Blister (PVC/PE/PVDC/Al): 14, 28, 30, 56, 84, 90 ili 98 filmom obloženih tableta, u kutiji.
If you get any of these symptoms or get short of breath, stop taking irbesartan and contact your doctor immediately.
Ako primijetite bilo koji od ovih simptoma ili nedostatak zraka, prestanite uzimati irbesartan i odmah se javite liječniku.
You may need to have blood checks if you take: - potassium supplements, - salt substitutes containing potassium, - potassium-sparing medicines (such as certain diuretics), - medicines containing lithium.
Pretrage krvi mogu biti neophodne ako uzimate: - nadomjestke kalija, - nadomjestke soli koje sadrže kalij, - lijekove koji čuvaju kalij (kao što su neki diuretici) ili - lijekove koji sadrže litij.
In patients insufficiently controlled with 150 mg once daily, the dose of Ifirmasta can be increased to 300 mg, or other antihypertensive agents can be added (see sections 4.3, 4.4, 4.5 and 5.1).
U bolesnika u kojih se bolest ne može dostatno kontrolirati dozom od 150 mg jedanput na dan, doza Ifirmaste može se povećati na 300 mg ili se mogu dodati drugi antihipertenzivi (vidjeti dijelove 4.3, 4.4, 4.5 i 5.1).
Following oral or intravenous administration of
Nakon oralne ili intravenske primjene
Ifirmasta belongs to a group of medicines known as angiotensin-II receptor antagonists.
Ifirmasta pripada skupini lijekova koja se naziva antagonisti receptora angiotenzina II.
In vitro studies indicate that irbesartan is primarily oxidised by the cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.
In vitro ispitivanja upućuju da se irbesartan primarno oksidira pomoću enzima CYP2C9 citokroma P450 dok izoenzim CYP3A4 ima neznatan učinak.
Because no information is available regarding the use of Ifirmasta during breast-feeding, Ifirmasta is not recommended and alternative treatments with better established safety profiles during breastfeeding are preferable, especially while nursing a newborn or preterm infant.
Budući da nema dostupnih podataka o primjeni Ifirmaste tijekom dojenja, ne preporučuje se primjena Ifirmaste tijekom dojenja i prednost treba dati drugoj terapiji s boljim profilom sigurnosti primjene, osobito kada se doji novorođenče ili nedonošče.
Rebound hypertension has not been observed.
Nije zabilježena pojava veće hipertenzije (tzv. rebound).
Diuretics and other antihypertensive agents:
Diuretici i drugi antihipertenzivni lijekovi:
Your doctor may need to change your dose and/or to take other precautions: - If you are taking an ACE-inhibitor or aliskiren (see also information under the headings “Do not take Ifirmasta” and “Warnings and precautions”).
Liječnik će Vam možda morati promijeniti dozu i/ili poduzeti druge mjere opreza: - Ako uzimate ACE inhibitor ili aliskiren (vidjeti također informacije pod naslovima
Based on its pharmacodynamic properties, irbesartan is unlikely to affect the ability to drive and use machines.
Na temelju njegovih farmakodinamičkih svojstava, nije vjerojatno da bi irbesartan utjecao na sposobnost upravljanja vozilima i rada sa strojevima.
It is unknown whether irbesartan or its metabolites are excreted in human milk.
Nije poznato izlučuju li se irbesartan ili njegovi metaboliti u majčino mlijeko.
The following table presents the adverse medicinal product reactions that were reported in placebocontrolled trials in which 1,965 hypertensive patients received irbesartan.
Sljedeća tablica prikazuje nuspojave prijavljene u placebom kontroliranim ispitivanjima, u kojima je 1965 hipertenzivnih bolesnika primalo irbesartan.
- The other ingredients are mannitol, hydroxypropylcellulose, low-substituted hydroxypropyl cellulose (LH-21), low-substituted hydroxypropyl cellulose (LH-11), talc, macrogol 6000, castor oil, hydrogenated in the core of tablet and polyvinyl alcohol, titanium dioxide (E171), macrogol 3000 and talc in film-coating.
- Drugi sastojci su manitol, hidroksipropilceluloza, nisko supstituirana hidroksipropilceluloza (LH-21), nisko supstituirana hidroksipropilceluloza (LH-11), talk, makrogol 6000 i hidrogenirano ricinusovo ulje u jezgri tablete te polivinilni alkohol, titanijev dioksid (E171), makrogol 3000 i talk u film ovojnici.
When angiotensin II antagonists are administered simultaneously with non-steroidal antiinflammatory medicinal products (i.e. selective COX-2 inhibitors, acetylsalicylic acid (> 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.
Kada se antagonisti angiotenzina II primjenjuju istodobno s nesteroidnim protuupalnim lijekovima (tj. selektivnim inhibitorima COX2, acetilsalicilatnom kiselinom (> 3 g/dan) i neselektivnim NSAIL) moguć je oslabljeni antihipertenzivni učinak.
Reproductive system and breast disorders: Uncommon: sexual dysfunction
Poremećaji reproduktivnog sustava i dojki: Manje često: seksualna disfunkcija
Ifirmasta prevents the binding of angiotensin-II to these receptors, causing the blood vessels to relax and the blood pressure to lower.
Ifirmasta sprječava vezanje angiotenzina II na te receptore, uzrokujući opuštanje krvnih žila i sniženje krvnog tlaka.
Talk to your doctor or pharmacist before taking Ifirmasta and if any of the following apply to you: - if you get excessive vomiting or diarrhoea, - if you suffer from kidney problems, - if you suffer from heart problems, - if you receive Ifirmasta for diabetic kidney disease.
Obratite se svom liječniku prije nego uzmete Ifirmastu ako se nešto od dolje navedenog odnosi na Vas: - ako Vas muči prekomjerno povraćanje ili proljev, - ako imate problema s bubrezima, - ako imate srčanih problema, - ako uzimate Ifirmastu zbog dijabetičke bolesti bubrega.
AngiotensinII is a substance produced in the body which binds to receptors in blood vessels causing them to tighten.
Angiotenzin II je tvar koja se stvara u tijelu i veže se na receptore u krvnim žilama te uzrokuje njihovo sužavanje.
As is the case with other medicinal products that affect the renin-angiotensin system, black hypertensive patients have notably less response to irbesartan monotherapy.
Kao što je to slučaj s ostalim lijekovima koji utječu na renin-angiotenzinski sustav, hipertenzivni bolesnici crne rase znatno slabije reagiraju na monoterapiju irbesartanom.
In patients with high blood pressure and type 2 diabetes with renal disease, dizziness when getting up from a lying or sitting position, low blood pressure when getting up from a lying or sitting position, pain in joints or muscles and decreased levels of a protein in the red blood cells (haemoglobin) were also reported.
U bolesnika s visokim krvnim tlakom i šećernom bolešću tipa 2 i bubrežnom bolešću također su prijavljeni omaglica i nizak krvni tlak nakon podizanja iz sjedećeg ili ležećeg položaja, bol u zglobovima ili mišićima i smanjene razine proteina u crvenim krvnim stanicama (hemoglobina).
Ifirmasta is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).
Ifirmasta se ne preporučuje uzimati u ranoj trudnoći i ne smije se uzimati ako ste trudni duže od 3 mjeseca jer može ozbiljno naškoditi Vašem djetetu ako se primjenjuje u tom stadiju (vidjeti dio o trudnoći).
In a randomised trial of 318 hypertensive children and adolescents aged 6 to 16 years, the following adverse reactions occurred in the 3-week double-blind phase: headache (7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%).
U trotjednoj dvostruko slijepoj fazi randomiziranog kliničkog ispitivanja u koje je bilo uključeno 318 djece i adolescenata s hipertenzijom u dobi od 6 do 16 godina pojavile su se sljedeće nuspojave: glavobolja (7,9%), hipotenzija (2,2%), omaglica (1,9%), kašalj (0,9%).
IRMA 2 was a placebo-controlled double blind morbidity study in 590 patients with type 2 diabetes, microalbuminuria (30-300 mg/day) and normal renal function (serum creatinine ≤ 1.5 mg/dl in males and < 1.1 mg/dl in females).
IRMA 2 bila je placebom kontrolirana, dvostruko slijepa studija morbiditeta u 590 bolesnika sa šećernom bolešću tipa 2, mikroalbuminurijom (30-300 mg/dan) i normalnom bubrežnom funkcijom (serumski kreatinin ≤ 1,5 mg/dl u muškaraca i < 1,1 mg/dl u žena).
The concomitant use of Ifirmasta with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena Ifirmaste s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
Symptomatic hypotension, especially after the first dose, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting.
Simptomatska hipotenzija, posebice nakon prve doze, može se pojaviti u bolesnika s hipovolemijom i/ili hiponatrijemijom zbog snažne diuretske terapije, restrikcijske dijete sa smanjenim unosom soli, proljeva ili povraćanja.
Approximately 33% of patients in the irbesartan group reached the primary renal composite endpoint compared to 39% and 41% in the placebo and amlodipine groups [20% relative risk reduction versus placebo (p = 0.024) and 23% relative risk reduction compared to amlodipine (p = 0.006)].
Oko 33% bolesnika u irbesartan skupini dostiglo je primarni kompozitni ishod za bubrežnu bolest, u usporedbi s 39% u placebo i 41% u amlodipin skupini [20% smanjenje relativnog rizika u odnosu na placebo (p=0,024) i 23% smanjenje relativnog rizika u usporedbi s amplodipinom (p=0,006)].
The pharmacokinetics of irbesartan were evaluated in 23 hypertensive children after the administration of single and multiple daily doses of irbesartan (2 mg/kg) up to a maximum daily dose of 150 mg for four weeks.
Farmakokinetika irbesartana proučavana je tijekom 4 tjedna na 23 djece s hipertenzijom nakon primjene jednokratne i višekratnih dnevnih doza (2 mg/kg), do maksimalne dnevne doze od 150 mg irbesartana.
Over a subsequent two week period where patients were re-randomized to either active medicinal product or placebo, patients on placebo had increases of 2.4 and 2.0 mmHg in SeSBP and SeDBP compared to +0.1 and -0.3 mmHg changes respectively in those on all doses of irbesartan (see section 4.2).
Tijekom sljedeća dva tjedna kada su bolesnici ponovo randomizirani ili na lijek ili na placebo, bolesnici na placebu imali su porast od 2,4 i 2,0 mmHg za SeSBP i SeDBP, u usporedbi s promjenama od +0,1 i -0,3 mmHg za bolesnike na svim dozama irbesartana (vidjeti dio 4.2).
There is no experience regarding the administration of Ifirmasta in patients with a recent kidney transplantation.
Nema iskustava s primjenom Ifirmaste u bolesnika kojima je nedavno transplantiran bubreg.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Ako ste trudni ili dojite, mislite da bi mogli biti trudni ili planirate imati dijete, obratite se svom liječniku ili ljekarniku prije uzimanja ovog lijeka.
Based on experience with the use of other medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium and is, therefore, not recommended (see section 4.4).
Na temelju iskustva s ostalim lijekovima koji utječu na renin-angiotenzinski sustav, istodobno uzimanje diuretika koji štede kalij, nadomjestaka kalija, nadomjestaka soli koji sadrže kalij ili ostalih lijekova koji mogu povećati serumsku razinu kalija (npr. heparin) može izazvati porast serumskog kalija te se, stoga, ne preporučuje (vidjeti dio 4.4).
In patients not adequately controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide (12.5 mg) to irbesartan once daily results in a further placebo-adjusted blood pressure reduction at trough of 7-10/3-6 mm Hg (systolic/diastolic).
U bolesnika koji nisu odgovarajuće kontrolirani samim irbesartanom, dodavanje niske doze hidroklorotiazida (12,5 mg) irbesartanu jednom dnevno rezultira daljnjim placebo-prilagođenim snižavanjem krvnog tlaka pri minimalnoj vrijednosti od 7-10/3-6 mmHg (sistolički/dijastolički).